| Title |
Changes in Utilization and Costs for Patients with Rheumatoid Arthritis, 1997 to 2006
|
|---|---|
| Published in |
PharmacoEconomics, October 2012
|
| DOI | 10.2165/11589470-000000000-00000 |
| Pubmed ID | |
| Authors |
Howard G. Birnbaum, Crystal Pike, Ritesh Banerjee, Tracy Waldman, Mary Cifaldi |
| Abstract |
Rheumatoid arthritis (RA) is a chronic autoimmune disease that often results in joint pain, inflammation and bone erosions. Perhaps the most notable change in RA treatment during the last decade is the advent of biologics, and, in particular, anti-tumour necrosis factor agents. Given these advances, it is useful to assess how healthcare and work-loss costs of patients with RA have changed. |
Mendeley readers
The data shown below were compiled from readership statistics for 66 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Spain | 1 | 2% |
| Colombia | 1 | 2% |
| Unknown | 63 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 12 | 18% |
| Student > Ph. D. Student | 9 | 14% |
| Student > Bachelor | 6 | 9% |
| Researcher | 6 | 9% |
| Student > Postgraduate | 5 | 8% |
| Other | 11 | 17% |
| Unknown | 17 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 32% |
| Pharmacology, Toxicology and Pharmaceutical Science | 5 | 8% |
| Economics, Econometrics and Finance | 3 | 5% |
| Biochemistry, Genetics and Molecular Biology | 2 | 3% |
| Agricultural and Biological Sciences | 2 | 3% |
| Other | 11 | 17% |
| Unknown | 22 | 33% |